Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.39 |
| ▸ | LAP3 | P28838 | 3/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7652855 | 0.98 | SMN1; SMN2 (0.47) | SMN1; SMN2ITGB3ITGAVALDH1A1FOLH1 | |
| SCHEMBL2234720 | 0.84 | MME (0.53) | SMN1; SMN2ITGB3ITGAVALDH1A1FOLH1 | |
| SCHEMBL18190834 | 0.84 | ALDH1A1 (0.58) | SMN1; SMN2ALDH1A1FOLH1LAP3MME | |
| SCHEMBL2234718 | 0.84 | MME (0.53) | SMN1; SMN2ITGB3ITGAVALDH1A1FOLH1 | |
| SCHEMBL21324906 | 0.82 | FOLH1 (0.51) | SMN1; SMN2ITGB3FOLH1ITGA2B | |
| SCHEMBL16557162 | 0.82 | FOLH1 (0.51) | SMN1; SMN2ITGB3FOLH1ITGA2B | |
| SCHEMBL2236885 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2ITGB3ITGAVALDH1A1FOLH1 | |
| SCHEMBL6763914 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2ITGB3ITGAVALDH1A1FOLH1 | |
| SCHEMBL2236878 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2ITGB3ITGAVALDH1A1FOLH1 | |
| SCHEMBL8142588 | 0.81 | CAD (0.39) | SMN1; SMN2ITGB3ITGAVALDH1A1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1051625-A1 | ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES | Du Pont Pharmaceuticals Company (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999038014-A1 | ASSESSING RISK FOR INTEGRIN ANTAGONIST/AGONIST MEDIATED DISEASES | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-07-29 | — | — | WO | disclosed |